Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2–9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/1/41 |
| _version_ | 1827663527580532736 |
|---|---|
| author | Anita Bakrania Gang Zheng Mamatha Bhat |
| author_facet | Anita Bakrania Gang Zheng Mamatha Bhat |
| author_sort | Anita Bakrania |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2–9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of improving the safety and efficacy of treatment for HCC. Although remarkable success has been achieved in nanomedicine research, there are unique considerations such as molecular heterogeneity and concomitant liver dysfunction that complicate the translation of nanotheranostics in HCC. This review highlights the progress, challenges, and targeting opportunities in HCC nanomedicine based on the growing literature in recent years. |
| first_indexed | 2024-03-10T00:44:02Z |
| format | Article |
| id | doaj.art-4f38bd641bf34280a45d65cf9f44e80f |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T00:44:02Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-4f38bd641bf34280a45d65cf9f44e80f2023-11-23T15:02:55ZengMDPI AGPharmaceutics1999-49232021-12-011414110.3390/pharmaceutics14010041Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer TreatmentAnita Bakrania0Gang Zheng1Mamatha Bhat2Toronto General Hospital Research Institute, Toronto, ON M5G 2C4, CanadaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, CanadaToronto General Hospital Research Institute, Toronto, ON M5G 2C4, CanadaHepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2–9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of improving the safety and efficacy of treatment for HCC. Although remarkable success has been achieved in nanomedicine research, there are unique considerations such as molecular heterogeneity and concomitant liver dysfunction that complicate the translation of nanotheranostics in HCC. This review highlights the progress, challenges, and targeting opportunities in HCC nanomedicine based on the growing literature in recent years.https://www.mdpi.com/1999-4923/14/1/41hepatocellular carcinomaliver cancernanoparticlenanomedicinegene therapy |
| spellingShingle | Anita Bakrania Gang Zheng Mamatha Bhat Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment Pharmaceutics hepatocellular carcinoma liver cancer nanoparticle nanomedicine gene therapy |
| title | Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment |
| title_full | Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment |
| title_fullStr | Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment |
| title_full_unstemmed | Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment |
| title_short | Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment |
| title_sort | nanomedicine in hepatocellular carcinoma a new frontier in targeted cancer treatment |
| topic | hepatocellular carcinoma liver cancer nanoparticle nanomedicine gene therapy |
| url | https://www.mdpi.com/1999-4923/14/1/41 |
| work_keys_str_mv | AT anitabakrania nanomedicineinhepatocellularcarcinomaanewfrontierintargetedcancertreatment AT gangzheng nanomedicineinhepatocellularcarcinomaanewfrontierintargetedcancertreatment AT mamathabhat nanomedicineinhepatocellularcarcinomaanewfrontierintargetedcancertreatment |